PL3400025T3 - Stosowanie gwajakolu w zapobieganiu i leczeniu choroby spichrzeniowej glikogenu - Google Patents
Stosowanie gwajakolu w zapobieganiu i leczeniu choroby spichrzeniowej glikogenuInfo
- Publication number
- PL3400025T3 PL3400025T3 PL17736394.2T PL17736394T PL3400025T3 PL 3400025 T3 PL3400025 T3 PL 3400025T3 PL 17736394 T PL17736394 T PL 17736394T PL 3400025 T3 PL3400025 T3 PL 3400025T3
- Authority
- PL
- Poland
- Prior art keywords
- guaiacol
- prevention
- treatment
- storage disease
- glycogen storage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/48—Reserve carbohydrates, e.g. glycogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275471P | 2016-01-06 | 2016-01-06 | |
| PCT/US2017/012455 WO2017120420A1 (en) | 2016-01-06 | 2017-01-06 | The use of guaiacol for the prevention and treatment of glycogen storage disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3400025T3 true PL3400025T3 (pl) | 2024-06-24 |
Family
ID=59274197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17736394.2T PL3400025T3 (pl) | 2016-01-06 | 2017-01-06 | Stosowanie gwajakolu w zapobieganiu i leczeniu choroby spichrzeniowej glikogenu |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10933031B2 (pl) |
| EP (1) | EP3400025B1 (pl) |
| ES (1) | ES2979171T3 (pl) |
| HU (1) | HUE066497T2 (pl) |
| IL (1) | IL260450B (pl) |
| PL (1) | PL3400025T3 (pl) |
| WO (1) | WO2017120420A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3866794B1 (en) * | 2018-10-17 | 2024-12-04 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| US11712432B2 (en) * | 2018-12-20 | 2023-08-01 | University Of Kentucky Research Foundation | Method of treating cancer with an elevated glycogen content |
| WO2021183554A1 (en) * | 2020-03-09 | 2021-09-16 | University Of Kentucky Research Foundation | Manipulating glycogen in alzheimer's disease, epilepsy, traumatic brain injury, and als as a treatment |
| CN120919090B (zh) * | 2025-10-16 | 2025-12-23 | 山东第一医科大学附属省立医院(山东省立医院) | 愈创木酚或其衍生物在制备预防或治疗代谢综合征药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06199695A (ja) | 1992-03-06 | 1994-07-19 | Yunie:Kk | 糖尿病改善治療剤 |
| GB0308952D0 (en) * | 2003-04-17 | 2003-05-28 | St Georges Entpr Ltd | Method |
| WO2005044247A1 (en) | 2003-11-07 | 2005-05-19 | Oaky Natural Co., Ltd | Pharmaceutical composition containing guaiacol derivatives and syringol derivatives extracted from natural plant vinegar |
| EP2132309A4 (en) * | 2007-02-23 | 2011-01-05 | Univ Florida | COMPOSITIONS AND METHODS OF TREATING GLYCOLOGICAL MEMORY DISEASES |
| EP2155197A4 (en) | 2007-03-09 | 2011-10-12 | Link Medicine Corp | TREATMENT OF LYSOSOMAL STORAGE DISEASES |
| US8679478B2 (en) * | 2010-10-04 | 2014-03-25 | Duke University | Methods of lysosomal storage disease therapy |
| WO2016090001A1 (en) | 2014-12-02 | 2016-06-09 | The Trustees Of Columbia University In The City Of New York | Deep intronic mutation found adult polyglucosan body disease and uses thereof |
| WO2016161086A1 (en) * | 2015-03-31 | 2016-10-06 | Duke University | Methods and compositions for treating glycogen storage diseases using agents that mimic or elevate cyclic amp |
-
2017
- 2017-01-06 EP EP17736394.2A patent/EP3400025B1/en active Active
- 2017-01-06 US US16/068,251 patent/US10933031B2/en active Active
- 2017-01-06 WO PCT/US2017/012455 patent/WO2017120420A1/en not_active Ceased
- 2017-01-06 ES ES17736394T patent/ES2979171T3/es active Active
- 2017-01-06 IL IL260450A patent/IL260450B/en unknown
- 2017-01-06 PL PL17736394.2T patent/PL3400025T3/pl unknown
- 2017-01-06 HU HUE17736394A patent/HUE066497T2/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL260450B (en) | 2022-06-01 |
| US20190015355A1 (en) | 2019-01-17 |
| EP3400025A4 (en) | 2019-12-11 |
| EP3400025B1 (en) | 2024-03-13 |
| EP3400025C0 (en) | 2024-03-13 |
| HUE066497T2 (hu) | 2024-08-28 |
| ES2979171T3 (es) | 2024-09-24 |
| EP3400025A1 (en) | 2018-11-14 |
| US10933031B2 (en) | 2021-03-02 |
| WO2017120420A1 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273550A (en) | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the I148M variant of PNPLA3 | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| IL258810A (en) | Materials and methods for treating glycogen storage disease type 1a | |
| IL269096A (en) | Treatment of glycogen storage disease 3 | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| GB201411496D0 (en) | Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy | |
| IL266047A (en) | Methods and preparations for the treatment of Fabry disease | |
| IL246579A0 (en) | Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease | |
| IL290955A (en) | Compounds for the treatment of glycogen storage diseases | |
| EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
| SMT202500469T1 (it) | Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla | |
| IL281585B (en) | Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use | |
| IL280570A (en) | Mini-GDE for the treatment of glycogen storage disease III | |
| ES2856150T5 (en) | Use of an inverse transcriptase inhibitor for the treatment and prevention of degenerative diseases | |
| SMT202300260T1 (it) | Composti a base di indolinoni e loro utilizzo nel trattamento di patologie fibrotiche | |
| GB201504387D0 (en) | Materials and methods for the treatment of vascular disease | |
| PL3400025T3 (pl) | Stosowanie gwajakolu w zapobieganiu i leczeniu choroby spichrzeniowej glikogenu | |
| GB201519557D0 (en) | Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions | |
| IL261834A (en) | Cd31shed agonists for use in the prevention and/or treatment of reperfusion injury | |
| GB201522329D0 (en) | Use of adjuvants for the prevention and/or treatment of autoimmune diseases | |
| EP3065548A4 (en) | Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases | |
| PL3166660T3 (pl) | Substancje i sposoby do zastosowania w profilaktyce i/lub leczeniu choroby Huntingtona | |
| IL259383A (en) | A compound for use in the prevention and treatment of neurodegenerative diseases | |
| IL252493A0 (en) | Compounds for use in the prevention or treatment of cancer | |
| IL251407B (en) | A multivalent compound for the treatment and prevention of brain damage |